17-(3-pyridyl)androsta-5,16-dien-3-one has been researched along with Cancer of Prostate in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alyamani, M; Auchus, RJ; Bishop, AC; Bunch, D; Dreicer, R; Garcia, JA; Li, Z; Liu, J; Sharifi, N; Upadhyay, SK | 1 |
1 other study(ies) available for 17-(3-pyridyl)androsta-5,16-dien-3-one and Cancer of Prostate
| Article | Year |
|---|---|
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.
Topics: 3-Hydroxysteroid Dehydrogenases; 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androgen Receptor Antagonists; Androgens; Androstenes; Animals; Benzamides; Biosynthetic Pathways; Biotransformation; Cell Division; Chromatin; Dihydrotestosterone; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Survival Analysis; Xenograft Model Antitumor Assays | 2015 |